Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

124.09 +6.97 (+5.95%)
Streaming Delayed Price Updated: 3:56 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,110,733
Open 117.66
Bid (Size) 124.00 (2)
Ask (Size) 124.11 (1)
Prev. Close 117.12
Today's Range 117.21 - 125.13
52wk Range 55.25 - 159.89
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
Sarepta stock has taken a beating this year, and it might not be over with the first-quarter report looming. 
Via Investor's Business Daily

Performance

YTD
+28.98%
+28.98%
1 Month
-3.01%
-3.01%
3 Month
+2.44%
+2.44%
6 Month
+9.41%
+9.41%
1 Year
-2.04%
-2.04%

More News

Read More
2 Biotech Stocks to Buy Hand Over Fist in April
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics: Q4 Earnings Insights
Via Benzinga
A Preview Of Sarepta Therapeutics's Earnings
Via Benzinga
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
Via Investor's Business Daily
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Via The Motley Fool
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
Via Benzinga
Got $1,000? Buy These Hot Growth Stocks Before They Take Off.
Via The Motley Fool
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
Via The Motley Fool
Sarepta Therapeutics to Present at Upcoming Investor Conferences
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Is It Too Late to Buy Sarepta Therapeutics Stock?
Via The Motley Fool
Earnings Scheduled For February 28, 2024
Via Benzinga
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
Via Benzinga
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight
Via Benzinga
Exposures Product Safety
Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.